Publication year: 2012
Source:Journal of Clinical Neuroscience
Anand Veeravagu, Robert E. Lieberson, Amanda Mener, Yi-Ren Chen, Scott G. Soltys, Iris C. Gibbs, John R. Adler, Ashley G. Tian, Steven D. Chang
Spinal cord intramedullary metastases are uncommon and treatment options are limited. We reviewed our experience treating these lesions with radiosurgery to assess safety and efficacy, and to define preliminary treatment recommendations. With Institutional Review Board approval, we identified nine patients with 11 metastases treated with radiosurgery at Stanford University Hospital, between 2000 and 2010. We also reviewed all available published series discussing the treatment of spinal cord metastases. Our patients ranged in age from 33years to 77years (median 63years) and included seven women and two men. Tumors ranged in size from 0.12cm3 to 6.4cm3 (median 0.48cm3). Five were from breast cancer, two were non-small cell lung cancers, one was a cystic adenocarcinoma, and one was from an epithelioid hemangioepithelioma. All patients had neurologic deficits and multiple other metastases. We delivered 14Gy to 27Gy (median 21Gy) in one to five (median 3) fractions. Complete follow-up was available for all nine patients. One patient remains alive 14months after therapy. Of the eight deceased patients, survival ranged from one month and two days to nine months and six days (median four months and four days). There were no local recurrences or worsened neurological deficits. To our knowledge this is the largest reported series of spinal cord intramedullary metastases treated with radiosurgery. Survival was poor due to systemic disease, but radiosurgery appears to be safe and prevented local recurrences. With fewer sessions than conventional radiation and less morbidity than surgery, we feel radiosurgery is appropriate for the palliative treatment of these lesions.
Source:Journal of Clinical Neuroscience
Anand Veeravagu, Robert E. Lieberson, Amanda Mener, Yi-Ren Chen, Scott G. Soltys, Iris C. Gibbs, John R. Adler, Ashley G. Tian, Steven D. Chang
Spinal cord intramedullary metastases are uncommon and treatment options are limited. We reviewed our experience treating these lesions with radiosurgery to assess safety and efficacy, and to define preliminary treatment recommendations. With Institutional Review Board approval, we identified nine patients with 11 metastases treated with radiosurgery at Stanford University Hospital, between 2000 and 2010. We also reviewed all available published series discussing the treatment of spinal cord metastases. Our patients ranged in age from 33years to 77years (median 63years) and included seven women and two men. Tumors ranged in size from 0.12cm3 to 6.4cm3 (median 0.48cm3). Five were from breast cancer, two were non-small cell lung cancers, one was a cystic adenocarcinoma, and one was from an epithelioid hemangioepithelioma. All patients had neurologic deficits and multiple other metastases. We delivered 14Gy to 27Gy (median 21Gy) in one to five (median 3) fractions. Complete follow-up was available for all nine patients. One patient remains alive 14months after therapy. Of the eight deceased patients, survival ranged from one month and two days to nine months and six days (median four months and four days). There were no local recurrences or worsened neurological deficits. To our knowledge this is the largest reported series of spinal cord intramedullary metastases treated with radiosurgery. Survival was poor due to systemic disease, but radiosurgery appears to be safe and prevented local recurrences. With fewer sessions than conventional radiation and less morbidity than surgery, we feel radiosurgery is appropriate for the palliative treatment of these lesions.
Sent with MobileRSS for iPhone
No comments:
Post a Comment